Hudson Bay Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,000	Closed	-$5.19M	–	1387
2025 Q1	$5.19M	Buy	150,000 +37,465	+33%	+$1.26M	0.02%	584
2024 Q4	$3.09M	Buy	+112,535	New	+$2.91M	0.01%	583
2024 Q3	–	Sell	-38,946	Closed	-$987K	–	865
2024 Q2	$987K	Buy	+38,946	New	+$1.06M	﹤0.01%	607
2023 Q2	–	Sell	-72,300	Closed	-$1.2M	–	859
2023 Q1	$1.2M	Buy	+72,300	New	+$843K	0.01%	573
2022 Q4	–	Sell	-30,000	Closed	-$298K	–	991
2022 Q3	$298K	Sell	30,000 -70,000	-70%	-$727K	﹤0.01%	911
2022 Q2	$908K	Buy	100,000 +50,000	+100%	+$418K	0.01%	951
2022 Q1	$508K	Buy	+50,000	New	+$513K	0.01%	875
2021 Q4	–	Sell	-20,000	Closed	-$937K	–	1092
2021 Q3	$937K	Buy	+20,000	New	+$1.07M	0.01%	762
2020 Q3	–	Sell	-10,000	Closed	-$326K	–	549
2020 Q2	$326K	Buy	+10,000	New	+$305K	0.01%	424

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Hudson Bay Capital Management's BBIO Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 150,000 shares — an estimated $5.19M sold.

Hudson Bay Capital Management first reported a position in BBIO in Q2 2020 and held it in 9 quarters. The position peaked at $5.19M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Hudson Bay Capital Management reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 150,000 BridgeBio Pharma shares in Q2 2025, an estimated $5.19M.
Hudson Bay Capital Management first reported a position in BridgeBio Pharma in Q2 2020 and held it in 9 quarters.
Hudson Bay Capital Management's BridgeBio Pharma position peaked at $5.19M in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.